A Case of Pyrazinamide Induced Fulminant Hepatic Failure

Standard antituberculous therapy, including isoniazid (INH), rifampin, ethambutol, and pyrazinamide (PZA), is widely used to treat active tuberculosis. The most important side effect is hepatotoxicity. In a standard four-drug regimen, PZA was the most common cause of drug-induced hepatitis and was dose-related. The incidence of drug-induced hepatitis is high at doses of 40∼70 mg/kg per day but has fallen significantly since the recommended dose was reduced. Liver toxicity induced by PZA is rare at doses of 25 mg/kg per day or less. PZA-induced fulminant hepatic failure is also rare but fatal. We report a case of fulminant hepatic failure caused by a re-challenge of PZA. (Tuberc Respir Dis 2007;63:435-439)

keywords: Drug induced hepatitis, Fulminant hepatic failure, Pyrazinamide, Drug induced hepatitis, Fulminant hepatic failure, Pyrazinamide

Reference

(amrevrespirdis1985;132) Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis,

(amrevrespirdis1979;119) Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis,

(amrevrespirdis1978;118) Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis,

(2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis,

(2005) National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection,

(1996) Hepatotoxicity of antituberculosis drugs,

(1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998,

(2003) American Thoracic Society/Centers for Disease Control/Infectious Diseases Society of America Treatment of tuberculosis,

(1996) Risk factors for side-effect of isoniazide, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis,

10.

(2002) Risk factors for hepatotoxicity associate with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three pubic health tuberculosis clinics,

11.

(2006) Risk factors of acute hepatic failure during antituberculosis treatment: two cases and literature review,

12.

(1995) Anti-tuberculosis medication and the liver: dangers and recommendations in management,

13.

(1995) Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid,

14.

(2006) Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy,

바로가기메뉴

Article Contents

Vol.63 No.5

A Case of Pyrazinamide Induced Fulminant Hepatic Failure

Abstract

Reference

Tuberculosis & Respiratory Diseases